Cell Biotech Co

Cell Biotech Co Operating Expenses

The Total Operating Expenses of Cell Biotech Co (049960.KQ) as of Nov 17, 2026 is 18.46 B KRW. In the previous year, Total Operating Expenses was 26.66 B KRW — a change of -30.74% (lower).

Operating Expenses

18.46 BKRW

YoY

-30.74%

Last updated:

Total Operating Expenses of Cell Biotech Co is 2025 18.46 B KRW. Total Operating Expenses of Cell Biotech Co was 2024 26.66 B KRW. It decreases by -30.74% lower compared to the previous year.

The Cell Biotech Co Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2018
26.33 B KRW
Jan 1, 2019
27.79 B KRW
Jan 1, 2020
28.60 B KRW
Jan 1, 2021
25.90 B KRW
Jan 1, 2022
29.37 B KRW
Jan 1, 2023
34.12 B KRW
Jan 1, 2024
26.66 B KRW
Jan 1, 2025
18.46 B KRW
The Cell Biotech Co Operating Expenses history
YEAROperating ExpensesYoY
18.46 BKRW-30.74%
26.66 BKRW-21.87%
34.12 BKRW+16.18%
29.37 BKRW+13.36%
25.90 BKRW-9.43%
28.60 BKRW+2.94%
27.79 BKRW+5.53%
26.33 BKRW+4.99%
25.08 BKRW+7.39%
23.35 BKRW+23.86%
18.85 BKRW+1.76%
18.53 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cell Biotech Co Stock analysis

What does Cell Biotech Co do? Cell Biotech Co., Ltd. generates revenue through the production and sale of probiotic lactobacillus products. The company manufactures lactic acid bacteria (LAB) powders, which serve as raw materials for foods and medicines targeting immunization enhancement and digestion improvement. Finished products containing LABs are sold for intestinal health improvement, carcinogen inhibition, and calcium supplementation, distributed domestically and internationally. The firm focuses on functional health applications within the probiotics market. The company's primary customers are domestic and international food and pharmaceutical manufacturers seeking functional ingredients, as well as end consumers purchasing finished probiotic products. LAB powders are supplied to food and medicine producers, while finished products reach consumers directly for health benefits. Distribution channels include both local and global markets, emphasizing the functional health segments of the industry. Cell Biotech's product portfolio centers on LAB-based solutions for health enhancement, with no additional brands or external partnerships mentioned in the business description. The company operates solely within the probiotics sector, leveraging its research and development capabilities to create products aligned with digestive and immune health needs. Cell Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cell Biotech Co stock

Total Operating Expenses of Cell Biotech Co is 18.46 B KRW in 2025.

Total Operating Expenses of Cell Biotech Co changed from 26.66 B KRW to 18.46 B KRW, representing a -30.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Cell Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Cell Biotech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Cell Biotech Co

All Key Metrics — Cell Biotech Co